Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-12-22
2009-02-10
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388150, C530S388220, C530S388750, C424S130100, C424S133100, C424S135100, C424S141100, C424S142100
Reexamination Certificate
active
07488802
ABSTRACT:
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
REFERENCES:
patent: 5837845 (1998-11-01), Hosokawa et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6808710 (2004-10-01), Wood et al.
patent: 2005/0180969 (2005-08-01), Hardy et al.
patent: 0 945 464 (1999-09-01), None
patent: WO 01/27272 (2001-04-01), None
patent: WO 01/27279 (2001-04-01), None
patent: WO 02/078731 (2002-10-01), None
patent: WO 2004/056875 (2004-07-01), None
Rudikoff et al., 1982, Proc. Natl. Acad. Sci. USA, , 79: 1979-1983.
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.
Lederman et al., Molecular Immunology, 1991, 28: 1171-1181.
Colman P.M., Research in Immunology, 1994, 145: 33-36.
Attwood T., Science, 2000, 290: 471-473.
Skolnick et al., Trends in Biotech., 2000, 18: 34-39.
Agata et al., “Expression of the PD-1 Antigen on the Surface of Stimulated Mouse T and B Lymphocytes,”Int'l Immunol. 8:765-772 (1996).
Ansari et al., The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice,J. Exp. Med. 198:63-69 (2003).
Bennett et al., “Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,”J. Immunol. 170:711-718 (2003).
Blazar et al., “PD-1 Engagement Provides an Inhibitory Signal Which Downregulates T Cell Alloresponses In Vivo,”Blood100:72a, Abstract No. 261 (2002).
Carreno et al., “The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses,”Annu. Rev. Immunol. 20:29-53 (2002).
Davies et al., “Affinity Improvement of Single Antibody VH Domains: Residues in All Three Hypervariable Regions Affect Antigen Binding,”Immunotechnology2:169-179 (1996).
Vaughan et al., “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library,”Nature Biotechnology14:309-314 (1996).
Accession No. Q15116, 2003.
Accession No. NM—008798, 2003.
U.S. National Phase U.S. Appl. No. 10/540,084, entitled “Antibodies Against PD-1 and Uses Therfor” (published as WO 04/056875).
De Kruif et al., “Selection and application of human single chain Fvantibody fragments from a semi-synthetic phage antibody display library with designated CDR3 regions” (1995)J. Mol. Biol. 248: 97-105.
Desmyter et al., “Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody” (2001)J. Biol. Chem. 276(28): 26285-26290.
Jirholt et al., “Exploring sequence space: shuffling in vivo formed complementarity determining regions into a master framework” (1998)Gene215: 471-76.
Levi et al., “A complementaity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro” (1993)Proc. Natl. Acad. Sci. USA., 90: 4374-78.
Marks et al., “By-passing immunization: building high affinity human antibodies by chain shuffling” (1992)Biotechnology10: 779-83.
Maynard and Georgiou, “Antibody engineering” (2000)Annu. Rev. Biomed. Eng. 2: 339-376.
Reiter et al., “An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface” (1999)J. Mol. Biol. 290:685-98.
Söderlind et al., “Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries” (2000)Nat. Biotech. 18: 852-856.
Söderlind et al., “Complementarity-determining region (CDR) implantation: a theme of recombination” (1999)Immunotechnology4:279-85.
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted fromEscherichia coli” (1989)Nature, 341: 544-46.
Welling et al., “A ten-residue fragment of an antibody (mini-antibody) directed against lysozyme as ligand in immunoafficity chromatography” (1991)J. Chromatography, 548:235-42.
Williams et al., “Development of biologically active peptides based on antibody structure” (1989)Proc. Natl. Acad. Sci. USA., 86: 5537-41.
Xu and Davis, “Diversity in the CDR3 region of VHis sufficient for most antibody specifications” (2000)Immunity, 13: 37-45.
Curetech Press Release, 2007, “CureTech announces receipt of a Notice of Allowance from the US Patent and Trademark Office”.
Curetech, http://www.curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14.
Holling et al., 2004, “Function and Regulation of MHC Class II Molecules in T-Lymphocytes: Of Mice and Men,” Human Immunology 65: 282-290.
Ladner et al., 2007, “Antibodies cut down to size,” Nat Biotechnol. Aug.;25(8):875-7.
Qiu et al., 2007, “Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting,” Nat Biotechnol. Aug. 2007;25(8):921-9. Epub.
Anaspec Online Catalog (Catalog No. 54662), “Anti-PDCD1 (CT).” www.anaspec.com/pdfs/54662.pdf.
Ishida Y. et al., 1992, “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” EMBO Journal, 11:11, pp. 3887-3895.
Nishimura, H. et al., 1999, “Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor,” Immunity. vol. 11, pp. 141-151.
Zhong, X. et al., 2004, “Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger,” Int'l Immunology, 16:8, pp. 1181-1188.
Andrews John
Bennett Frances K.
Carreno Beatriz M.
Carter Laura L.
Collins Mary
MedImmune Limited
Ouspenski Ilia
Wolf Greenfield & Sacks P.C.
Wyeth
LandOfFree
Antibodies against PD-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against PD-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against PD-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113690